Strategic Growth Target expansion opportunities in B-cell autoimmune diseases and multiple sclerosis markets where TG Therapeutics has FDA approval and ongoing development, aligning outreach with their commercial-stage focus and pipeline.

Financing Opportunity Leverage TG Therapeutics’ large funding base and recent $750M senior secured credit to propose large-scale collaboration, licensing, or co-development deals that fit their growth trajectory and capital deployment needs.

Acquisition & Licensing Position in-licensing or exclusive worldwide rights for complementary B-cell targets or autoimmune indications (e.g., Azer-cel extensions) to accelerate TG’s pipeline diversification and market potential.

Data-Driven Partnerships Engage around advanced analytics, clinical trial support, or real-world evidence partnerships leveraging TG’s HIPAA-compliant tech stack and Medidata capabilities to de-risk development programs.

Strategic Conferences Align outreach with TG’s investor and industry presence at major conferences and summits to propose joint ventures, strategic investments, or milestone-based collaborations that appeal to management and investors.